{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=40", "query": { "intervention": "Induction Phase", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 2299, "total_pages": 230, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T11:33:24.645Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06332534", "title": "Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 111, "start_date": "2024-08-08", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 12, "location_summary": "Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06332534" }, { "nct_id": "NCT03289299", "title": "Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "International Myeloma Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2018-05-25", "completion_date": "2031-11-15", "has_results": false, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 10, "location_summary": "Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03289299" }, { "nct_id": "NCT03358706", "title": "A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Crohn Disease", "Ulcerative Colitis" ], "interventions": [ { "name": "Ustekinumab IV Infusion", "type": "DRUG" }, { "name": "Ustekinumab SC Injection", "type": "DRUG" }, { "name": "Midazolam 2 mg", "type": "DRUG" }, { "name": "Warfarin 10 mg", "type": "DRUG" }, { "name": "Vitamin K 10 mg", "type": "DRUG" }, { "name": "Omeprazole 20 mg", "type": "DRUG" }, { "name": "Dextromethorphan 30 mg", "type": "DRUG" }, { "name": "Caffeine 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2018-02-02", "completion_date": "2021-11-22", "has_results": false, "last_update_posted_date": "2025-08-21", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 3, "location_summary": "Cypress, California • Miami Springs, Florida • Durham, North Carolina", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Miami Springs", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03358706" }, { "nct_id": "NCT03999749", "title": "A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2019-06-11", "completion_date": "2030-04-07", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03999749" }, { "nct_id": "NCT02655458", "title": "Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "autologous PBMC reconstitution", "type": "OTHER" }, { "name": "ASCT", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hearn Jay Cho", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2016-01", "completion_date": "2017-07-13", "has_results": false, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02655458" }, { "nct_id": "NCT02792192", "title": "Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bacille Calmette-Guérin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-06-13", "completion_date": "2020-09-29", "has_results": true, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 8, "location_summary": "Stanford, California • Chicago, Illinois • Baltimore, Maryland + 5 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "The Bronx", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02792192" }, { "nct_id": "NCT04261387", "title": "LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Radiation Dermatitis" ], "interventions": [ { "name": "LUT014 Gel", "type": "DRUG" }, { "name": "Placebo for LUT014 Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lutris Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2021-01-30", "completion_date": "2022-07-15", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 2, "location_summary": "Columbus, Georgia • Shreveport, Louisiana", "locations": [ { "city": "Columbus", "state": "Georgia" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04261387" }, { "nct_id": "NCT00938626", "title": "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells", "type": "BIOLOGICAL" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2009-10", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-09-23", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00938626" }, { "nct_id": "NCT03059485", "title": "DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "DC/AML Fusion Vaccine", "type": "BIOLOGICAL" }, { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2017-06-01", "completion_date": "2027-06-04", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Madison, Wisconsin", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03059485" }, { "nct_id": "NCT00553644", "title": "Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2007-11-15", "completion_date": "2014-01-21", "has_results": true, "last_update_posted_date": "2018-10-30", "last_synced_at": "2026-10-27T11:33:24.645Z", "location_count": 82, "location_summary": "Anaheim, California • Baldwin Park, California • Bellflower, California + 62 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "Harbor City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00553644" } ] }